Targeting mTOR dependency in pancreatic cancer
暂无分享,去创建一个
Amy Y. M. Au | A. Biankin | S. Grimmond | S. Pimlott | K. Anderson | D. Chang | Jianmin Wu | C. Scarlett | N. Jamieson | O. Sansom | G. Kalna | K. Oien | S. Karim | J. Morton | C. McKay | Agata Mrowinska | T. Evans | Saadia A. Karim | M. Pająk | Douglas C. Morran | C. Carter | G. Gillen | S. Champion | D. C. Morran | C. Carter | Genome Initiative | Ross Carter | Jeffry Evans | Sean M Grimmond
[1] R. Rad,et al. Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer. , 2013, Cancer cell.
[2] J. Asara,et al. Stimulation of de Novo Pyrimidine Synthesis by Growth Signaling Through mTOR and S6K1 , 2013, Science.
[3] U. Sauer,et al. Quantitative Phosphoproteomics Reveal mTORC1 Activates de Novo Pyrimidine Synthesis , 2013, Science.
[4] A. Maitra,et al. Phosphorylation of ribosomal protein S6 attenuates DNA damage and tumor suppression during development of pancreatic cancer. , 2013, Cancer research.
[5] N. Sonenberg,et al. eIF4E/4E-BP ratio predicts the efficacy of mTOR targeted therapies. , 2012, Cancer Research.
[6] Lincoln D. Stein,et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes , 2012, Nature.
[7] G. Kristiansen,et al. The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma , 2012, Nature.
[8] Carlos Cuevas,et al. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. , 2012, Cancer cell.
[9] A. Rust,et al. Sleeping Beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma , 2012, Proceedings of the National Academy of Sciences.
[10] D. Tuveson,et al. nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. , 2012, Cancer discovery.
[11] J. Norman,et al. Rab25 and CLIC3 Collaborate to Promote Integrin Recycling from Late Endosomes/Lysosomes and Drive Cancer Progression , 2012, Developmental cell.
[12] David Olmos,et al. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Jennifer P Morton,et al. MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma , 2011, Clinical Cancer Research.
[14] Gerald C. Chu,et al. PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-κB-cytokine network. , 2011, Cancer discovery.
[15] Pierre Michel,et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.
[16] Rugang Zhang,et al. Activation of the PIK3CA/AKT pathway suppresses senescence induced by an activated RAS oncogene to promote tumorigenesis. , 2011, Molecular cell.
[17] D. Richel,et al. mTOR inhibitor treatment of pancreatic cancer in a patient With Peutz-Jeghers syndrome. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] M. Nowak,et al. Distant Metastasis Occurs Late during the Genetic Evolution of Pancreatic Cancer , 2010, Nature.
[19] A. Ashworth,et al. LKB1 Haploinsufficiency Cooperates With Kras to Promote Pancreatic Cancer Through Suppression of p21-Dependent Growth Arrest , 2010, Gastroenterology.
[20] R. Wolff,et al. Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies , 2010, BMC Cancer.
[21] N. Sonenberg,et al. mTORC1-Mediated Cell Proliferation, But Not Cell Growth, Controlled by the 4E-BPs , 2010, Science.
[22] Paul Timpson,et al. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer , 2010, Proceedings of the National Academy of Sciences.
[23] A. Kibel. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial , 2009 .
[24] N. Sonenberg,et al. p53-dependent translational control of senescence and transformation via 4E-BPs. , 2009, Cancer cell.
[25] David Allard,et al. Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer , 2009, Science.
[26] D. Guertin,et al. The Pharmacology of mTOR Inhibition , 2009, Science Signaling.
[27] Jeffrey W. Clark,et al. Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] R. Motzer,et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial , 2008, The Lancet.
[29] Wei Chen,et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] Wolfgang A Weber,et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. , 2007, The Lancet. Oncology.
[31] A. Toker. Faculty Opinions recommendation of mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. , 2006 .
[32] Gordon B Mills,et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. , 2006, Cancer research.
[33] Huajun Yan,et al. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade , 2005, Molecular Cancer Therapeutics.
[34] F. Khuri,et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. , 2005, Cancer research.
[35] R. Hruban,et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. , 2005, Cancer cell.
[36] E. Petricoin,et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. , 2003, Cancer cell.
[37] S. Gambhir. Molecular imaging of cancer with positron emission tomography , 2002, Nature Reviews Cancer.
[38] G. Koehl,et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor , 2002, Nature Medicine.
[39] R H Hruban,et al. Progression model for pancreatic cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[40] Otto Muzik,et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography , 1998, Nature Medicine.
[41] D. V. Von Hoff,et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] A. Gingras,et al. Rapamycin blocks the phosphorylation of 4E‐BP1 and inhibits cap‐dependent initiation of translation. , 1996, The EMBO journal.
[43] N. Sigal,et al. The immunosuppressive macrolides FK-506 and rapamycin act as reciprocal antagonists in murine T cells. , 1990, Journal of immunology.
[44] D. Shibata,et al. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes , 1988, Cell.
[45] G. Kristiansen,et al. The deubiquitinase USP 9 X suppresses pancreatic ductal adenocarcinoma , 2012 .
[46] A. Stütz. Immunosuppressive macrolides. , 1992, Transplantation proceedings.